

Remarks/Arguments:

I. Status of the Application

Claim 47 is amended herein. Claims 13-19, 21-27, 35-37 and 44-46 are withdrawn from consideration as a result of a restriction requirement. Claims 1-12, 20, 28-34 and 38-43 have been cancelled. Consequently, claims 47-60 remain pending and under examination in the application.

II. Key Points of the Invention

Due to the fact that the Examiner assigned to examine the application has changed, the Applicant considers that for a better understanding of the invention and its impact in the technical development, it would be worthwhile to explain briefly the key points of the invention in view of the particularities of the cell wall of *Mycobacterium tuberculosis* and tuberculosis disease.

The present application pertains to a new and inventive immunotherapeutic agent for the combined treatment of tuberculosis in association with other drugs.

Tuberculosis is a worldwide chronic infectious disease. Tuberculosis is not a viral disease. Tuberculosis in humans is caused by a bacterium: *Mycobacterium tuberculosis*.

The preventive treatment of tuberculosis is based on a vaccine containing attenuated live bacilli of a *Mycobacterium bovis* strain called BCG, but the treatment of infected persons involves the administration of antibiotics over long periods of time (6-9 months). Consequently, there is a need for increasing the efficacy of that antibiotic treatment.

The immunotherapeutic agent which is the subject of this application is obtained by a new and inventive process, and it is surprisingly suitable for the combined treatment of tuberculosis in association with other drugs, thereby shortening the treatment of latent tuberculosis infection.

These results are shown in the experimental models of mice (Example 3 of the application) and also in experimental models of mice and guinea pigs in the article (published by one of the inventors after filing of the application) P. J. Cardona, RUTI: *A new chance to shorten the treatment of latent tuberculosis infection*, Tuberculosis, 2006, 86, 273-289. A copy of this article is attached hereto as Exhibit A.

A key point of the invention disclosed in the present application is a new and inventive process for preparing an immunotherapeutic agent that contains cell wall fragments. The process comprises the following steps:

- a) culturing cells of a virulent *Mycobacterium tuberculosis* - complex (MTB-C) strain for a period of at least three weeks,
- b) homogenizing the cells in the presence of a non-ionic surfactant to produce a homogenate comprising non-fragmented cells, cell wall fragments, and solubilized cell compounds, wherein the non-ionic surfactant is selected from the group consisting of alkylphenol ethoxylates and ethoxylated sorbitan esters,
- c) centrifuging the homogenate to separate cell wall fragments from the non-fragmented cells and the solubilized cell compounds, and
- d) washing the cell wall fragments and further inactivating any remaining virulent cells.

The combination of the key steps a) and b) affords a new and inventive product: an immunotherapeutic agent which is suitable for the combined treatment of tuberculosis in association with other drugs shortening the treatment of latent tuberculosis infection.

The immunotherapeutic agent obtained according to this method shows an unexpected synergism for treating tuberculosis when combined with other drugs (see paragraph [0047] of the application, and Example 3, Section IV, Table 6, Trial 4 compared with Trials 2 and 3);

TABLE 6

Trial	Antibiotic	Liposomal immunotherapeutic agent	log ₁₀ UFC/mL
1	No	No	5.37 ± 0.27
2	Yes	No	3.29 ± 0.8*
3	No	Yes	5.69 ± 0.22
4	Yes	Yes	0.69 ± 0**

*= statistically significant value compared to trials 1, 3 and 4 for p < 0.05;

**= statistically significant value compared to trials 1, 2 and 3 for p < 0.05

From these results it is apparent that the combination of the immunotherapeutic agent of the present invention with antibiotics (Trial 4) gave unexpectedly better results (i.e. synergism) than treatment with antibiotics alone (Trial 2) and treatment with the immunotherapeutic agent alone (Trial 3).

The Applicant respectfully submits that:

- the prior art does not disclose such process for preparing the immunotherapeutic agent disclosed in the present application, and
- the combination of the prior art documents would not have led an ordinarily skilled person in the art to arrive at that process with a reasonable expectation of success, for the reasons explained subsequently in this response.

For a better understanding of the contribution of the invention to the advancement of technical development in the relevant field, the uniqueness of the cell wall of *Mycobacterium tuberculosis* and the particularities of tuberculosis disease must be taken into account.

The cell wall of *M. tuberculosis* is thick and waxy and it is a major determinant of virulence for the bacterium. This cell wall is highly complex in comparison with the cell wall of other Gram positive bacteria. It is characterized by a high content of lipids, complex polysaccharides, and some proteins. Some of those compounds are toxic, for example the compound named 6,6'-dimycolate, also known as cord factor, produced by virulent mycobacterial strains.

The particularities of tuberculosis disease constitute another point which must be considered.

The distinction between tuberculosis infection, also known as Latent Tuberculosis Infection (LTBI), and tuberculosis disease should be emphasized.

A person becomes infected with tuberculosis when a strain of *Mycobacterium tuberculosis* complex (MTB-C) reaches the alveoli in the lungs.

Infected people do not present symptoms and cannot spread the disease but exhibit a positive response to the tuberculin test.

LTBI is mainly characterized by "latent" bacilli, which are non-replicating bacilli. A person may remain infected for years. Some factors may activate the latent bacilli and the patient may then develop the disease presenting typical symptoms due to actively growing bacilli.

Current standard treatment to fight tuberculosis in people having LTBI or already having developed the disease involves the administration of several drugs (i.e. chemotherapy) for a long period of time. Isoniazid is an example of such a drug.

Chemotherapy acts on metabolically active growing bacilli. After a short period of chemotherapy, most of the metabolically active growing bacilli are supposed to be eliminated. However, latent bacilli still persist, leading to a state of chronic tuberculosis infection. In order to completely eliminate the infection, a long-term period of chemotherapy (from 6-9 months) is needed.

This long-term therapy makes treatment-compliance extremely difficult. If the treatment is stopped before its end, the patient may develop the disease again. Further, non-compliance may induce the development of strains resistant to chemotherapy, which makes the eradication of tuberculosis more difficult.

The immunotherapeutic agent which is the subject of the present application is currently being used in Phase II clinical trials, without any reports of any remarkable adverse effect.

Consequently, the Applicant respectfully submits that the immunotherapeutic agent of the present application contributes significantly to improving the treatment of tuberculosis infection.

II. Rejections under 35 U.S.C. §112

Claims 47-60 have been rejected under 35 USC §112, second paragraph, as being indefinite because independent claim 47 includes the phrase "further treating the cell wall fragments to inactivate any remaining virulent cells".

The Applicant respectfully submits that claim 47 is not indefinite, as an ordinarily skilled person in the art would readily understand the scope of the claim in view of the explanation given in the specification. See, for example, paragraph [0030]), which explains that the sediment undergoes a chemical method (e.g., treatment with formol) or a physical method (e.g., treatment in autoclave or pasteurization) to guarantee the total inactivation of the MTB-C cells that could have been viable after fragmentation and purification.

However, in order to expedite the prosecution of the application, Claim 47 has been amended to introduce the following wording: "inactivating any remaining virulent cells."

Support for this amendment is found throughout the application as originally filed, including in paragraph [0030], wherein it is disclosed that the inactivation of any remaining virulent cells can be carried out by means of chemical or physical treatments, which are well known to the skilled person in the art.

III. Rejections under 35 U.S.C. § 103

III.1.- Rejection over *Kumazawa et al.*, in view of *Ragland*

Claims 47-49 and 51-55 have been rejected under 35 U.S.C. § 103(a) as allegedly being obvious over *Kumazawa et al.* (Japan J Microbiol 1976; 20:183-190) in view of *Ragland* (US 4,744,984).

The Applicant respectfully traverses.

To establish a *prima facie* case of obviousness:

- the cited references must disclose all of the claim limitations, and
- there must be a reasonable expectation of success.

The Applicant respectfully submits that these requirements are not fulfilled in the present case and that therefore the obviousness rejection should be withdrawn.

The combination of the immunotherapeutic agent of the present invention with other drugs for the combined treatment of tuberculosis did not yield predictable results, but synergy, as shown in Example 3, Section IV, Table 6, Trial 4 compared with Trials 2 and 3. The effect of this combination was not predictable from the disclosures of the cited prior art documents.

i) Kumazawa discloses the preparation of a water-soluble extract obtained by chemical hydrogenolysis of bacterial cells, but not the preparation of cell wall fragments

Kumazawa addresses to the preparation of a water-soluble adjuvant (MAF 3) from delipidated cells of a virulent *M. tuberculosis* strain by hydrogenolysis and gel filtration.

On the contrary, the present application is directed to an immunotherapeutic agent comprising cell wall fragments, which are insoluble in water (see Example 1, in particular paragraphs [0056]-[0064]).

Moreover, claim 47 makes clear that the immunotherapeutic agent corresponds to the non-solubilized cell wall fragments.

The immunotherapeutic agent of the patent application differs substantially from the water-soluble adjuvant of *Kumazawa*:

- According to *Kumazawa*, the adjuvant was readily soluble in water (see page 185, right column, Section RESULTS, lines 5-6), whereas the immunotherapeutic agent of Applicant's invention is insoluble in water: cell wall fragments are isolated from an aqueous solution and washed repeatedly with aqueous PBS buffer.

- The adjuvant obtained according to *Kumazawa* does not contain cell wall fragments, but water extracts from hydrogenolyzed cells, i.e., chemically modified cells (see Abstract, line 1).
- Moreover, the MAF 3 of *Kumazawa* consisted of heteropolymers composed of neutral sugar and mucopeptide having a molecular weight of approx. 16,000 daltons (see page 188, right column, last paragraph). It contained appreciable amounts of various aminoacids other than the typical amino acids present in the mycobacterial cell wall (see page 189, left column, lines 8 to 11). The immunotherapeutic agent of the present patent application comprises cell wall fragments.

The Applicant respectfully submits that these essential differences between the water-soluble adjuvant MAF 3 of the *Kumazawa* reference and the immunotherapeutic agent of the present invention are the result of the different processes used to obtain each of them.

The following table compares the process disclosed by *Kumazawa* and the process of the present application to make apparent that there are substantial differences between both processes:

Process steps	Kumazawa	Patent application Example 1
1	MTB-C cells were cultured for 8 weeks	MTB-C cells are cultured for at least 3 weeks
2	Cells were killed by heating at 100° C and washed with water	Cells are <u>homogenized in the presence of a non-ionic surfactant</u> selected from the group consisting of alkylphenol ethoxylates and sorbitan ester ethoxylates
3	Cells were <u>delipidated</u> with acetone, chloroform and methanol, more than six times	-
4	Cells were <u>hydrogenolyzed</u> with hydrogen and Pd as catalyst	-
5	Treated cells were extracted exhaustively with water, and the water extracts collected	Insoluble cell wall fragments were separated from non-fragmented cells and solubilized cell compounds, washed and inactivated
6	Water extracts were lyophilized	A dispersion of <u>insoluble cell wall fragments</u> is lyophilized
7	The water-soluble extracts were dissolved and applied to a gel permeation column	-
8	MAF 3 <u>water-soluble extract</u> were eluted as third fraction, and lyophilized	-

The Examiner states that the teaching of *Kumazawa* differs from the instant claims only in that the non-ionic surfactant was absent from the homogenizing process. The Applicant respectfully disagrees. From the above table, it is apparent that the process disclosed by *Kumazawa* differs substantially from the process of the present application, and not only by the absence of the non-ionic surfactant.

The Examiner states that the hydrogenolysis homogenized the bacterial cells. The Applicant respectfully disagrees. A skilled person knows that hydrogenolysis is a chemical reaction whereby a carbon-carbon or carbon-heteroatom single bond is cleaved by hydrogen. In fact, hydrogenolysis produces a chemical modification of the cells, whereas the homogenization in the present invention involves the physical breaking of the cells to obtain small fragments.

The Applicant respectfully submits that these differences in the process will impart distinctive structural characteristics to the final product.

Further, the immunotherapeutic agent of the instant invention has been found to be suitable for the treatment of tuberculosis. In particular, it has been unexpectedly found to have a synergistic activity when given as a combined treatment with drugs (e.g. isoniazid or rifampicin) for the treatment of tuberculosis (see paragraph [0047] and Section IV of Example 3, more in particular, Table 6, Trial 4 compared to Trials 2 and 3).

Advantageously, due to this synergistic activity, the immunotherapeutic agent of the instant invention allows reducing the time of treatment with those drugs (see paragraph [0118]) and thus also reducing the risk of developing resistance. This is highly desirable, in view of the fact that, prior to the instant invention, the period of treatment of tuberculosis with said drugs was of several months (see paragraphs [0006] and [0007]).

In fact, *Kumazawa* refers to the use of a *Mycobacterium tuberculosis* strain, but in this reference there is no hint that the obtained water-soluble adjuvant would be suitable for the treatment of tuberculosis, let alone in combination with other drugs.

The combination of the immunotherapeutic agent of the present application with other drugs for the combined treatment of tuberculosis did not yield predictable results, but synergy, as shown in Example 3, Section IV, Table 6. The effect of this combination was not predictable from the disclosure of *Kumazawa*.

In summary, *Kumazawa et al.* does not disclose or suggest the preparation of an immunotherapeutic agent comprising a cell wall fraction, but the isolation of a water-soluble extract from hydrogenolyzed cells of a virulent strain of MTB-C, that is, a water-soluble extract from chemically modified cells. Further *Kumazawa* does not suggest, much less disclose, that

the water-soluble extracts would be suitable for the treatment of tuberculosis, let alone in combination with other drugs.

ii) Ragland discloses the preparation of an antiviral immunotherapeutic agent comprising deproteinized cell walls

Ragland is directed to the preparation of an antiviral immunotherapeutic agent, which comprises an effective amount of a deproteinized mycobacterial cell wall suspension, from which nucleic acid and lipids have been extracted by treatment with a detergent and phenol.

In particular, *Ragland* discloses the preparation of an antiviral immunotherapeutic agent, which comprises an effective amount of a deproteinized mycobacterial cell wall suspension from *Mycobacterium phlei*. This strain is a non-tuberculous strain, showing a fast growth and rarely causing human pathology.

Ragland discloses the use of the modified cell wall from *M. phlei* to develop an antiviral immunotherapeutic agent, not an immunotherapeutic agent for the treatment of tuberculosis by itself or in combination with other drugs.

Tuberculosis is not a viral disease, but a bacterial disease whose responsible agent in humans is *Mycobacterium tuberculosis*, a rod-shaped bacterium.

Consequently, it is apparent that the antigenic features of MTB-C differ substantially from the antigenic features of the cell wall of *M. phlei* disclosed by *Ragland*.

The immunotherapeutic agent of the present application differs substantially from the immunotherapeutic agent disclosed by *Ragland* because:

- 1) It uses MTB-C as *Mycobacterium tuberculosis* strain, not *M. phlei*, which is a non-tuberculous strain.
- 2) The immunotherapeutic agent of Applicant's invention addresses the treatment of tuberculosis, whereas the immunotherapeutic agent disclosed by *Ragland* shows antiviral features.

- 3) The immunotherapeutic agent of Applicant's invention is suitable for the treatment of tuberculosis and it shows synergism when combined with other drugs.

According to the Examiner, *Ragland* supplements *Kumazawa* by establishing it was well known in the art to prepare mycobacteria wall extract using non-ionic surfactant such as Triton® X-100, as an alternative or additional measure for physical disruption of bacterial cell walls.

The Examiner concludes that it would have been obvious to the skilled person in the art to modify the composition as taught by *Kumazawa* by including the optional Triton® X-100 treatment as taught by *Ragland* with a reasonable expectation of success.

The Applicant respectfully disagrees.

As already discussed above, *Kumazawa* addresses the preparation of a water soluble adjuvant from delipidated cells of a virulent *M. tuberculosis* strain by hydrogenolysis and gel filtration. This water-soluble product is substantially different of the immunotherapeutic agent of the present application, because it is water-soluble and is obtained by chemical cleavage of bacterial cells.

The Applicant submits that the treatment of that water soluble adjuvant with Triton® X-100, as disclosed by *Ragland*, would not have led to the present immunotherapeutic agent.

Ragland discloses the treatment of deproteinized cell wall fragments with a combination of urea, phenol and Triton® X-100 to remove nucleic acids and/or lipids in order to obtain an antiviral immunotherapeutic agent.

From the disclosure, it is apparent that *Ragland* has nothing to do with immunotherapeutic agents for the treatment of tuberculosis, let alone such agents in combination with other drugs for treating tuberculosis.

It is clear that the process disclosed in *Ragland* differs substantially from the process of the present application. The differences in the processes consequently result in the preparation of different products.

In fact, *Ragland* discloses the preparation of modified bacterial cell walls from a non-tuberculous strain *M. phlei* that is capable of stimulating the immune system of an animal or man in such a way as to cause the body to neutralize or abort a viral infection. *Ragland* neither discloses nor suggests the process of the present application for preparing an immunotherapeutic agent useful for the treatment of tuberculosis, a bacterial disease, in combination with other drugs.

Consequently, the Applicant respectfully submits that the immunotherapeutic agent obtained according to the process of the Instant application clearly must be different in structure and properties from the cell wall extract which would be prepared according to the process disclosed by *Kumazawa* in combination with the teaching of *Ragland*.

It is respectfully submitted that the teaching of *Kumazawa* in combination with *Ragland* would not have motivated a person of ordinary skill in the art to prepare an immunotherapeutic agent, in accordance with the process of the present patent application, which would be suitable for the combined treatment of tuberculosis with other drugs with a reasonable expectation of success.

To establish a *prima facie* case of obviousness it is fundamental that there must be a reasonable expectation of success.

As discussed previously, it is important to distinguish between prophylaxis of tuberculosis, currently performed with immunogenic BCG vaccination, and treatment of tuberculosis currently performed with long-term chemotherapy treatments, both directed against growing bacilli.

Moreover, there is no indication either in *Kumazawa* or in *Ragland* that the respective products obtained by practice of the reference disclosures would be suitable for the treatment of tuberculosis, particularly when used in combination with other drugs.

According to Dr. Cardona's declaration (submitted February 5, 2010), several previous attempts by others in identifying an immunotherapeutic agent useful for the treatment of tuberculosis failed. Even vaccines previously probed to be immunogenic when given to uninfected people, were found to be ineffective when given as treatment of infected patients. Furthermore, the development of an immunotherapeutic agent raised safety concerns due to the fact that known

immunogenic compositions, including the current prophylactic treatment with BCG vaccination, induce severe toxic reactions when given to infected mammals.

Thus, as supported by Dr. Cardona's declaration, at the time the instant invention was made one would not have had a reasonable expectation of succeeding in finding an immunotherapeutic agent against latent tuberculosis, based on a non-purified cell extract of a virulent tuberculosis strain, that would result in effectively reducing the number of bacilli and, importantly, without inducing toxic responses, so that it could be potentially used to significantly reduce the currently employed long-term (6 to 9 month) chemotherapy treatment.

Dr. Cardona's declaration also discusses examples of the application, in particular Example 3, Section IV, effectively showing the unexpected activity of the claimed immunotherapeutic agent. As explained by Dr. Cardona, the immunotherapeutic agent of the invention, after a very short chemotherapy treatment, extremely reduces the number of bacilli including latent bacilli in the lungs in a murine model of chronic tuberculosis infection.

The combination of the immunotherapeutic agent of the present patent application with other drugs for the combined treatment of tuberculosis did not yield predictable results, but rather synergy, as shown in Example 3, Section IV, Table 6, Trial 4 compared to Trials 2 and 3. The effect of this combination was not predictable from the disclosure of *Kumazawa* in view of *Ragland*.

Moreover, despite being a non-purified mixture of antigens obtained from a virulent strain and despite giving repeated doses of the Immunotherapeutic agent instantly claimed, no local toxicity was observed in the treated animals.

For the foregoing reasons, Applicant respectfully submits that claims 47-49 and 51-55 are not rendered obvious by the cited references and request that this rejection under 35 U.S.C. § 103 be reconsidered and withdrawn.

III.2.- Rejection over *Kumazawa et al.* in view of *Ragland* and further in view of *Mohr et al.*

Claim 50 stands rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over *Kumazawa et al.* in view of *Ragland*, and further in view of *Mohr et al.* (US 7,214,651).

According to the Examiner, the combined teaching of *Kumazawa* in view of *Ragland* does not mention the ethylene oxide content of the ethoxylates, but *Mohr* teaches that ethoxylates having 5-7 or more than 7 EO units are effective disinfectants for disinfection against mycobacterium.

The Applicant respectfully disagrees.

Mohr addresses methods and compositions for a concentrated alkaline disinfectant, which includes a quaternary ammonium salt, an alcohol ethoxylate with between 5 and 7 EO units, alkylamine, an acid and an aromatic alcohol (see Abstract).

Mohr also teaches that those disinfectant compositions are useful as disinfectants for instruments and for controlling mycobacteria.

According to *Mohr*, the invention relates to the use of alcohol ethoxylates having 5-7 EO units for improving the mycobactericidal activity of a disinfectant which contains quaternary ammonium salt (see column 1, lines 18 to 21).

It is well known to the skilled person in the art that quaternary ammonium salts are disinfecting agents used in household and industrial compositions for disinfecting hard surfaces, clothes and swimming pools, for example.

It is also well known to the skilled person in the art that alcohol ethoxylates having 5-7 EO units are emulsifying agents used in household and industrial formulations for improving, for example, wetting and dispersing capacity.

Mohr teaches that the invention is based, *inter alia*, on the recognition that the use of alcohol ethoxylates having 5-7 EO units can improve the activity of a defined disinfectant (i.e., the quaternary compound) against mycobacteria (see column 3, lines 19 to 26).

The Applicant respectfully submits that *Mohr* does not teach the use of a non-ionic surfactant with 5-7 EO units in the homogenization of mycobacteria, as used in the present patent application.

The Applicant considers that *Mohr* relates to the technical field of disinfecting of hard surfaces using quaternary compounds in combination with specific non-ionic surfactants, which show an improved performance in front of mycobacteria. Thus, the disclosure of *Mohr* is clearly far away from the technical field of the present patent application.

According to *Mohr*, the disclosed composition is suitable for disinfecting hard surfaces due to the presence of a quaternary compound, whose effect is improved by the presence of the alcohol ethoxylate. That is, the composition destroys bacteria that are living on hard surfaces due to the presence of a quaternary compound, which shows better performance due to the non-ionic surfactant.

Taking into account that disclosure, the Applicant considers that the ordinarily skilled person in the art would not have been led to use a non-ionic surfactant to homogenize cells of a virulent strain of MTB-C in order to obtain an Immunotherapeutic agent which is suitable for the treatment of tuberculosis, particularly in combination with other drugs.

Consequently, the Applicant respectfully submits that the secondary reference *Mohr* cannot cure the deficiencies of the combination of *Kumazawa* and *Ragland*, as already discussed previously, because *Mohr* does not teach or suggest any method for preparing cell wall fragments comprising the features of the method of the present patent application.

Claim 50 is dependent from claim 49. Since, as discussed above, claim 49 is not obvious over *Kumazawa* in view of *Ragland*, then dependent claim 50, which further limits the immunotherapeutic agent, must also be non-obvious.

For these reasons, the Applicant respectfully requests that the Examiner withdraw the rejection.

III.3.- Rejection over *Kumazawa et al.* in view of *Ragland* and further in view of *Lyons et al.*

Claims 47-49 and 51-55 were rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over *Kumazawa et al.* in view of *Ragland*, and further in view of *Lyons et al.* (Infect Immunity 2002; 70:5471-8).

According to the Examiner, *Lyons* supplements the combined teaching of *Kumazawa* and *Ragland* by establishing it is well known in the art that the cell wall extract on *Mycobacteria* strain H37Rv has been used as a vaccine composition for treating *M. tuberculosis* infection.

The Examiner concluded that it would have been obvious to the skilled person to use either *M. tuberculosis* strain Aoyama B as taught by *Kumazawa* or strain H37Rv as taught by *Lyons* with a reasonable expectation of success.

The Applicant respectfully disagrees.

Lyons et al. discloses investigations related to understanding how prior vaccination may alter very early events in the *M. tuberculosis*-infected lung. In this context, *Lyons et al.* demonstrate that primary alveolar macrophages harvested from BCG-vaccinated guinea pigs and stimulated in vitro with a variety of stimuli including cell walls of virulent strain H37Rv produce significantly higher levels of mRNA and protein for IL-8 than do alveolar macrophages harvested from nonvaccinated guinea pigs.

Lyons et al. does not disclose any method for preparing cell walls because they were provided by the laboratory of John Belisle from the Department of Microbiology, Colorado State University, Fort Collins.

According to the information available on the Web page of that University regarding Tuberculosis Vaccine Testing and Research Materials Contract (see the document attached as Exhibit B hereto), that cell wall fraction likely had been prepared in the following way:

Reagent:

Cell Wall Fraction, CW

Default Quantity:

1 mg

Production system:

Each strain is grown to late-log phase (day 14) in glycerol-alanine-salts (GAS) medium, washed with PBS pH 7.4 and inactivated by gamma-irradiation. The bacilli are suspended (2 g/ml) in PBS containing 8 mM EDTA, DNase, RNase and a proteinase inhibitor tablet, and broken in a French Press pressure cell at 4°C. Unbroken cells are removed by low speed (3,000 x g) centrifugation. The cell wall is isolated by centrifugation at 27,000 x g for one hour and washed 2 times in PBS. The final cell wall pellet is suspended and dialyzed in 0.01M ammonium bicarbonate, quantified by BCA protein assay for protein content, and stored at -80°C.

Notes:

This preparation contains proteins and non-protein compounds such as mAGP.

This process used for preparing the cell wall fragments differs substantially from the process of the present patent application, as shown in the following table:

Process steps	<i>Lyons et al.</i>	Patent application Example 1
1	MTB-C were cultured for 14 days	MTB-C cells are cultured for <u>at least 3 weeks</u>
2	Cells were inactivated by gamma-irradiation	-
3	Cells were disrupted by pressure in the presence of DNase, RNase and proteinase inhibitor	Cells are homogenized <u>in the presence of a non-ionic surfactant</u> selected from the group consisting of alkylphenol ethoxylates and sorbitan ester ethoxylates
3	Insoluble cell wall fragments were separated from non-fragmented cells and solubilized cell compounds, and washed	Insoluble cell wall fragments were separated from non-fragmented cells and solubilized cell compounds, washed and inactivated

From the above table, it is apparent that the process of the present patent application differs substantially from the process disclosed by reference in *Lyons et al.* This process differs in two essential points: culturing time and the presence of a non-ionic surfactant in the homogenization step.

Lyons et al. cannot cure the deficiencies of the combination of *Kumazawa* and *Ragland* as already discussed, because *Lyons et al.* does not teach or suggest any method for preparing cell wall fragments, which comprises the features of the method of the present patent application.

Lyons et al. discloses the use of strain H37Rv to prepare cell wall fragments according to a substantially different method, which are used for other purposes than the treatment of tuberculosis in combination with other drugs.

Kumazawa addresses the preparation of a water soluble adjuvant from *M. tuberculosis* strain Aoyama B. The use of either this strain or H37Rv strain, as suggested by the Examiner in view of *Lyons et al.*, would not lead to the immunotherapeutic agent of the present patent application, which is formed by cell wall fragments insoluble in water.

Moreover, the combination of the immunotherapeutic agent of the present patent application with other drugs for the combined treatment of tuberculosis did not yield predictable results, but synergy, as shown in Example 3, Section IV, Table 6, Trial 4 compared to Trials 2 and 3. The effect of this combination was not predictable from the disclosure of *Kumazawa* in view of *Ragland* and further in view of *Lyons*.

For these reasons, the Applicant respectfully requests the Examiner to withdraw the instant rejection.

III.4.- Rejection over *Kumazawa et al.* in view of *Ragland* and further in view of *Dhiman et al.*

Claim 56 was rejected under 35 U.S.C. 103(a) as allegedly being obvious over *Kumazawa et al.* in view of *Ragland*, and further in view of *Dhiman et al.* (Indian J Exp Biol 1999; 37: 1157-66).

According to the Examiner, *Dhiman* supplements the combined teachings of *Kumazawa* and *Ragland* by establishing it was well known in the art that liposome may be present in the mycobacteria cell wall composition as an adjuvant.

The Examiner concludes that it would have been obvious to the skilled person in the art to include liposome in the composition of mycobacterial cell wall extracts with a reasonable expectation of success.

The Applicant respectfully disagrees.

Dhiman is a review article collecting different approaches for the control of tuberculosis disease, specially focused on defined proteins of bacterial origin, identified as targets for vaccine development.

Among the large quantity of data that is included in the article, *Dhiman* discloses that a cell wall composition in liposome shows a lower efficacy compared with the standard vaccine BCG (see page 1163, Table 4).

From that disclosure, the skilled person would not have been prompted to use cell wall fragments in liposome form because the efficacy is worse than the standard vaccination procedure.

Moreover, *Dhiman* cannot cure the deficiencies of the combination of *Kumazawa* and *Ragland* as already discussed, because *Dhiman* does not teach or suggest any method for preparing cell wall fragments which comprises the features of the method of the present patent application.

Dhiman does not teach or suggest the use of cell wall fragments for the treatment of tuberculosis in combination with other drugs, either in the form of liposomes or in any other form.

Claim 56 is dependent on claim 54. Since, as discussed above, claim 54 is not obvious over *Kumazawa* in view of *Ragland*, then dependent claim 56, which further limit the composition, must also be non-obvious.

Moreover, the combination of the immunotherapeutic agent of the present patent application with other drugs for the combined treatment of tuberculosis did not yield predictable results, but synergy, as shown in Example 3, Section IV, Table 6, Trial 4 compared to Trials 2 and 3.

The effect of this combination was not predictable from the disclosure of *Kumazawa* in view of *Ragland* and further in view of *Dhiman*.

For these reasons, the Applicant respectfully requests the Examiner to withdraw the instant rejection.

III.5.- Rejection over *Kumazawa et al.* in view of *Ragland* and *Dhiman et al.* and further in view of *Parikh*

Claims 57-60 were rejected under 35 U.S.C. 103(a) as allegedly being obvious over *Kumazawa et al.* in view of *Ragland*, and *Dhiman et al.*, and further in view of *Parikh* (US 5,785,975).

According to the Examiner, *Parikh* supplements the combined teaching of *Kumazawa*, *Ragland* and *Dhiman* by establishing it was known in the art that a liposome has many forms and components including sterols, phosphatidylcholine, and a bacteria vaccine composition may comprise phosphatidylcholine liposome and vitamin E.

The Examiner concludes it would have been obvious to the skilled person in the art to include additional elements in the composition of the mycobacterial cell wall extracts with a reasonable expectation of success.

The Applicant respectfully disagrees.

Parikh describes phospholipid adjuvant compositions and vaccine formulations (Abstract), stating that examples of vehicles with adjuvant-like activities include water/oil emulsions, oil/water emulsions, microencapsulation, and liposomes (paragraph 15). In Example II, *Parikh* discloses a vaccine emulsion formulation comprising a mixture of beta-glucanphospholipid conjugate, phosphatidylcholine and vitamin E (paragraph 44).

However, *Parikh* does not cure the deficiencies of *Kumazawa* and *Ragland*, as already discussed, since *Parikh* neither teaches nor suggests any method for preparing cell wall fragments. Moreover, *Parikh* discloses a vaccine containing a beta-glucanphospholipid conjugate, which is not used in the invention of the present application.

The Examiner has relied on *Parikh* for the feature that the pharmaceutical composition in the form of liposomes further comprises vitamin E. Since, as discussed above, claims 47 and 54 are non-obvious over *Kumazawa* in view of *Ragland*, then dependent claims 57-60, which further limit the composition, must also be non-obvious.

Moreover, the combination of the immunotherapeutic agent of the present patent application with other drugs for the combined treatment of tuberculosis did not yield predictable results, but synergy, as shown in Example 3, Section IV, Table 6, Trial 4 compared to Trials 2 and 3. The effect of this combination was not predictable from the disclosure of *Kumazawa* in view of *Ragland* and *Dhiman* and further in view of *Parikh*.

For these reasons, the Applicant respectfully requests the Examiner to withdraw the instant rejection.

IV. Concluding Remarks

The immunotherapeutic agent of the instant invention is not only characterized by containing cell wall fragments from a virulent *Mycobacterium tuberculosis* - complex (MTB-C) strain, but also by the features implied by the process of manufacture:

- a) culturing cells of a virulent *Mycobacterium tuberculosis* - complex (MTB-C) strain for a period of at least three weeks,
- b) homogenizing the cells in the presence of a non-ionic surfactant to produce a homogenate comprising non-fragmented cells, cell wall fragments, and solubilized cell compounds, wherein the non-ionic surfactant is selected from the group consisting of alkylphenol ethoxylates and ethoxylated sorbitan esters,
- c) centrifuging the homogenate to separate cell wall fragments from the non-fragmented cells and the solubilized cell compounds, and
- d) washing the cell wall fragments and further inactivating any remaining virulent cells.

It is apparent to a person having ordinary skill in the art that these process steps will impart distinctive structural characteristics to the final product

None of the documents mentioned by the Examiner, taken alone or in combination, teaches or suggests the preparation of an immunotherapeutic agent containing cell wall fragments from a virulent strain of *Mycobacterium tuberculosis* by the process of the present application.

Consequently, the Applicant respectfully submits that it is apparent that the immunotherapeutic agent obtained according to the process of the instant application must be different in structure and properties from the cell wall extracts prepared according to the processes disclosed in the prior art documents mentioned by the Examiner.

Further, none of the documents quoted by the Examiner, taken alone or in combination, suggests to the person having ordinary skill in the art to prepare an immunotherapeutic agent by the process of the present application which would be suitable for the treatment of tuberculosis, particularly in combination with other drugs.

Furthermore, none of the documents cited by the Examiner contains any teaching, suggestion or motivation whatsoever that would have made obvious, at the time of the invention, the unexpected synergistic effect of the immunotherapeutic agent of the instant invention which is observed when the agent is given in combination with other drugs suitable for the treatment of tuberculosis (cf. paragraph [0047] and Section IV of Example 3, more in particular, table 6).

Based on the above comments, it is respectfully requested that all rejections under 35 USC § 103 be withdrawn.

Early and favorable action in the application is respectfully requested. If any issues should remain, the Examiner is encouraged to contact Applicants' legal representatives at the number listed below.

Respectfully submitted,



Jacques L. Etkowicz, Reg. No. 41,738
Stephen D. Harper., Reg. No. 33,243
Attorneys for Applicants

Attachments:

- P. J. Cardona, RUTI: *A new chance to shorten the treatment of latent tuberculosis infection*, Tuberculosis, 2006, 86, 273-289 (Exhibit A)
- Colorado State University Information (Exhibit B)

Dated: April 13, 2011

P.O. Box 980
Valley Forge, PA 19482
(610) 407-0700

The Director is hereby authorized to charge or credit Deposit Account No. **18-0350** for any additional fees, or any underpayment or credit for overpayment in connection herewith.



RUTI: A new chance to shorten the treatment of latent tuberculosis infection

Pere-Joan Cardona

Unitat de Tuberculosi Experimental, Department of Microbiology, Fundació Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol and Universitat Autònoma de Barcelona, Hospital Universitari "Germans Trias i Pujol". Crta del Canyet s/n, 08916 Badalona, Catalonia, Spain

Received 12 December 2005; accepted 31 January 2006

KEYWORDS

Mycobacterium tuberculosis;
Immunotherapy;
Chemotherapy;
Latent tuberculosis infection;
Foamy macrophages

Summary Treatment of latent tuberculosis infection (LTBI) requires a long period of chemotherapy (9 months), which makes treatment-compliance extremely difficult. Current knowledge of latent bacilli and of the lesions with which they are associated suggests that these bacilli survive in granulomas with a central necrotic core and an outermost layer of foamy macrophages (FM) that represent an important immunosuppressive barrier. The presence of FM, which is especially strong in mice, explains not only the kinetics of the drainage of dead bacilli, debris and surfactant, but also how latent bacilli can escape from the granuloma and re-grow in the periphery, particularly in the alveolar spaces where they can disseminate easily.

RUTI, a therapeutic vaccine made of detoxified, fragmented *Mycobacterium tuberculosis* cells, delivered in liposomes, was used to assess its effectiveness in a short period of chemotherapy (1 month). The rationale of this therapy was first to take advantage of the bactericidal properties of chemotherapy to kill active growing bacilli, eliminate the outermost layer of FM and reduce local inflammatory responses so as to avoid the predictable Koch phenomenon caused by *M. tuberculosis* antigens when given therapeutically. After chemotherapy, RUTI can be inoculated to reduce the probability of regrowth of the remaining latent bacilli.

RUTI has already demonstrated its efficacy in controlling LTBI in experimental models of mice and guinea-pigs after a short period of chemotherapy; these experiments in animals showed the induction of a mixed Th1/Th2/Th3, polyantigenic response with no local or systemic toxicity. Local accumulation of specific CD8 T cells and a strong humoral response are characteristic features of RUTI that explain its protective properties; these are particular improvements when compared with BCG, although the regulatory response to RUTI may also be an important advantage.

Tel.: +34 93 497 88 94; fax: +34 93 497 88 95.

E-mail address: pcardona@ns.hugtip.scs.es.



Further experiments using bigger animals (goats and mini-pigs) will provide more data on the efficacy of RUTI before starting phase I clinical trials.
& 2006 Elsevier Ltd. All rights reserved.

Introduction: what is a latent bacillus?

Despite this being a simple question, finding an appropriate answer is crucial to demonstrate the validity of any new treatment against latent *Mycobacterium tuberculosis* bacilli; latent bacilli are responsible for the long period of treatment currently required for sterilizing lesions infected with *M. tuberculosis*.

The nature of latent bacilli and their ability to survive "in vitro" in low pO_2 conditions, and even in anaerobiosis,¹ has been widely studied. To survive in low pO_2 , bacilli appear to acquire a state of nonreplicant persistence (NRP).² Huge lesions with intragranulomatous necrosis (IN) that are induced in tuberculosis (TB) may develop such an extreme anaerobic environment,² supporting the idea that latency induced by low pO_2 occurs in lesions. However, direct measurements have never demonstrated the presence of anaerobiosis in TB lesions and factual support for the hypothesis is lacking. Furthermore, IN is a "living" tissue, full of collagen fibers, that also needs a physiological environment for survival. Anaerobiosis, therefore, appears unlikely in such a setting. Even if such atmosphere with low pO_2 be induced in calcified lesions, experimental models³ demonstrate that the period in which the bacilli may survive in this environment is definitely finite. Moreover, microaerobiosis is usual in the host tissues⁴ and, therefore, not only latent bacilli but also actively growing cells may adapt to this environment. Furthermore, experiments in knock out (KO) mice lacking functional genes essential for triggering a competent immune response demonstrated that active growing bacilli can be found inside massive lesions with abundant IN, expected to have a low pO_2 .^{5,6}

Some authors defined latent bacilli as those present in the tissues of mice treated with chemotherapy for a long time, whose presence was not detected in cultures until a few months after the end of the treatment; this process was favored by the administration of cortisone. This experimental model, characterized a long time ago, is known as the Cornell model.⁷ In the Cornell model bacilli do not have to resist an extremely low pO_2 . However, patients with latent tuberculosis infection (LTBI) face circumstances different from

those in the Cornell model.⁸ Usually, people with LTBI display a cell-mediated and antibody-mediated immune response that controls progression of the infection in the initial focus of infection and in the local draining lymph nodes (the "Ghon complex") by inducing a strong granulomatous infiltration,⁹ a process which does not happen in the Cornell model. Besides, it is currently accepted that the population obtained with the Cornell model is special and is not considered to be a good model of latent bacilli, but rather of "persistent" bacilli.^{10,11} Persistence implies that a special population of bacilli subsists the period of chemotherapy, probably through acquiring tolerance to antibiotics,^{11,12} although its mechanism remains poorly understood.

Other authors focused on the hypothesis that latent bacilli have to adapt to a lack of nutrients, thus resembling the bacterial population found in the steady state of conventional liquid cultures.¹³ Thus the term "dormant" was established to define bacilli that were "in a state of low metabolic activity and unable to divide or to form a colony without a preceding resuscitation in liquid medium, which may either occur spontaneously or require the provision of compounds (growth factors) present in the supernatant of growing cells".^{13,14} These authors considered the *in vitro* "dormant" form as the equivalent to the one obtained *in vivo* with the Cornell model, representing an extreme form of viability, close to the death of the cell. However, the exquisitely fastidious requirements needed for regrowth of these "dormant" bacilli are difficult to reconcile with the conditions faced by latent bacilli *in vivo*, bacilli which are, however, able to reactivate after a long period of time to induce TB disease.

Finally, there is the observation made a long time ago that the bacillary population obtained from the lungs of chronically infected mice has a greater resistance to heat stress (53 °C) than the bacillary population in the acute phase.¹⁵ The same author submitted "in vitro" cultures, young (exponential phase) and old (steady-state phase) to the same conditions and obtained a higher resistance to heat stress in the latter. This observation led to the conclusion that a slower growth rate made bacilli from the chronic phase more resistant to stress. Consistent with this hypothesis, Muñoz-Elias et al.¹⁶

recently reviewed this work and demonstrated that the chronic phase of infection in murine TB was accompanied by a reduction in the rate of bacterial cell-division.

The current consensus is that the chronic phase in the experimental murine model is a consequence of the specific immunity elicited against growing *M. tuberculosis*.¹⁷ This immunity triggers a number of mechanisms that induces the death of most bacterial cells (i.e. low pH, reactive oxygen intermediates, reactive nitrogen intermediates, etc.). As a consequence of this strong immune response, the population in the chronic phase comes from bacilli able to adapt to stress and thus, a high proportion of these bacilli are the same as so-called "latent" bacilli. Therefore, in our opinion latent bacilli are those that can resist the immunological response triggered by the host. However, it is noteworthy that not all bacilli from the chronic phase are in a latent state, consistent with the observations in patients with LTBI.

Immunopathology of the scenario of local infection

At the beginning of *M. tuberculosis* infection, the development of IN suggests the occurrence of the Koch phenomenon, observed in most mammals.¹⁸ The Koch phenomenon probably arises from a local Schwartzman reaction.^{19,20} The following sequence of events are postulated: infected macrophages in the granuloma produce high concentrations of TNF; the presence of this cytokine makes the site responsive to endotoxin-like molecules (like trehalose dimycolate^{21,22}), which exist in the cell wall of *M. tuberculosis* when the lack of specific immunity allows an exponential growth of bacilli; the corresponding reaction triggers a "first wave" of latent bacilli (i.e., bacilli surviving the initial inflammatory response), which are then trapped in the collagen fibers that "take the place" of the destroyed infected macrophages.

A "second wave" of latent bacilli may be triggered by the induction of specific immunity, which activates the infected macrophages to destroy most of the initial bacillary bulk. This response to specific immunity is observed in the experimental murine model of aerosol-induced TB, where IN is not usually induced and where antibody-mediated immunity is not triggered during this initial phase of infection. In this model, a 90% reduction of the bacillary concentration is caused by the activation of infected macrophages by T cells that produce IFN- γ and by the cytolysis induced by

specific CD8 cells.²³⁻²⁵ However, during the chronic phase, new cells appear at the outermost layer of the granulomas, occupying the alveolar spaces: these cells are the foamy macrophages (FM).^{26,27} FM are usually seen in all inflammatory responses in the lung, and not only in infectious inflammatory responses.²⁸ The function of FM is to phagocytose the necrotic material produced after an interstitial inflammatory response (i.e. dead host cells, the surfactant secreted locally and the dead *M. tuberculosis* cells remaining), to rebuild the original parenchyma.²⁹ These newly accumulated macrophages can leave the lesion through the alveolar spaces to reach the upper bronchi, where they are swallowed and enter the stomach. In the context of *M. tuberculosis* infection, the FM may be also originated from the initial infected macrophage population, following the killing of most of bacilli.²⁹ The aerosol murine model presents an interesting scenario because large quantities of bacilli are observed in granulomas that are initially ill-defined, during the acute phase of infection, whereas no acid fast bacilli are seen in their center during the chronic phase (at 6 weeks post infection); instead, single bacilli are present in the periphery, inside FM located in the alveolar spaces. Further characterization of these structures demonstrated a progressive increase of inducible nitric oxide (NO) synthase (iNOS) during the chronic phase of infection, which is the main enzyme responsible for NO production and which is localized almost exclusively in FM.²⁷ Hence, since FM produce NO and may suppress the activating specific T cells, both Th1 and Th2,³⁰ they constitute an immunosuppressive outermost ring around the lesion.³¹⁻³⁴

In the acute phase of *M. tuberculosis* infection, production of RNI is linked to a Th1 activation, and is paramount for the control of the infection³⁴ including the control of chronic infection in the murine model of TB.³⁵ However, at the same time, NO production, which is stimulated not only by IFN- γ but also TNF³⁶⁻³⁸ and IL-4 in human monocytes³⁹ and pulmonary epithelial cells,⁴⁰ also generates a negative feed back in the production of these cytokines thus generating a local immunosuppression both for Th1 and Th2 responses.^{41,42} The anti-inflammatory role of NO has been suggested by others,⁴³ taking into account that RNI are also extremely toxic to the host cells⁴⁴ and not all of them are able to kill *M. tuberculosis*, (for example, peroxy nitrite anion,⁴⁵ which, at the same time exerts a negative feedback against NO production).⁴⁶

FM have been extensively studied in the induction of atherosclerosis. In this case, their origin is

linked to an inflammatory process. In particular, it has been demonstrated that TNF is able to upregulate the lectin-like oxidized LDL receptor (LOX-1)⁴⁷ which increases the uptake of Oxidized LDL (OxLDL)⁴⁸ thus contributing to lipidosis and FM formation. In this case, the increase of LOX-1 was linked to a NO deficiency. Thus, the presence of NO does not favor the formation of FM. On the other hand, it has been recently demonstrated that oxidation of LDL is not a limiting factor for induction of FM as they can be also formed with native LDL⁴⁹ through a mechanism of macropinocytosis. Additional evidence in support of the view that inflammatory response is paramount in the induction of FM comes from the studies with IL-10 KO mice, which exhibited a threefold increase in cholesterol accumulation in macrophages, whereas over-expression of IL-10 in either C57BL/6 or Ldlr^{-/-} mice resulted in a significant decrease.⁵⁰ Furthermore, treatment of Ldlr^{-/-} mice with the nonsteroidal anti-inflammatory drug indomethacin or a COX-2-selective inhibitor, rofecoxib, resulted in a significant reduction in lesion size.⁵¹

In the context of the lung infection it must be taken into account that the presence of large amounts of a lipoprotein surfactant complex may also play an important role. The name "surfactant" is derived from its well-defined ability to lower surface tension at the interface of alveolar gas and the liquid hypophase,⁵² and also participate in the control of parenchyma destruction.⁵³ In this regard, when alveolar macrophages are chronically exposed to high quantities of surfactant they become FM.⁵⁴ The presence of killed *M. tuberculosis* bacilli or cell wall fragments from them also induces the formation of FM.²⁹ Furthermore, some components of *M. tuberculosis* are also known to induce iNOS production.⁵⁵ This may explain why apparently incoherent circumstances may coexist in the chronic phase of *M. tuberculosis* infection in mice, i.e. the presence of FM in the context of NO expression and the continued local immunosuppression over a long period. Besides, as NO production in the FM may occur in the context of insufficient macrophage activation, as a consequence of the suppression of Th1 response, this could explain why the bacilli that shelter in them can survive. It is known that RNI bactericidal effect is concentration dependent.⁵⁶ Thus, paradoxically, RNI are known to be able to even induce mycobacterial growth, and have been implied in the hormesis phenomenon, i.e. stimulatory effects caused by low levels of a potentially toxic agent.⁵⁷

Recently, several reports have shown that low or nontoxic concentrations of NO donors (DETA-NO) modulate the expression of a 48-gene regulon,

which is expressed by *M. tuberculosis* both in vivo and in vitro and prepares bacilli for survival during long periods of in vivo dormancy. In conjunction with low concentrations of oxygen in tissues, NO can play a role in the initiation and maintenance of the latent state of *M. tuberculosis* within granulomas, which could be a mechanism for the tubercle bacillus to persist in FM of the host.⁵⁸⁻⁶¹ In addition, Darwin et al. have shown that mutation of the proteasome of *M. tuberculosis* sensitized bacilli to NO, suggesting that mycobacterial proteasome serves as a defense against nitrosative stress.⁶²

FM also produce large quantities of transforming growth factor-beta (TGF- β) and thus may induce apoptosis of effector T cells.⁶³ They are known also to display high levels of DEC-205, (i.e., a marker characteristic of dendritic cells), but down regulate MHC class II markers, thus rendering them inadequate for antigen presentation (although no data on MHC Class II markers are available). Besides, FM appear to resist apoptosis.⁶⁴ Thus, FM appear to be a kind of sanctuary for those bacilli that survive the immunological response, in addition to also being a source of local immunosuppression. Furthermore, we must also consider the hypothesis that FM cannot produce mature endosomes and induce stress conditions due to having too much material to process. This in turn, may encourage bacillary growth at the periphery of the granuloma.

Finally, it has been reported that treatment with isoniazid (INH) and rifampicin results in the elimination of the FM outermost layer,⁶⁵ but it is still not clear if this phenomenon is linked to the inhibition of the regrowth of the bacilli and thus the reduction of the inflammatory response, or by the direct reduction of the inflammatory response caused by the antibiotic, as demonstrated for moxifloxacin.^{66,67}

Figure 1 represents a time-related description of the murine model of TB with regards to growing/dead bacilli, synthesis of surfactant, IFN- γ and TNF, and FM. All these data are based on published work.^{16,26} However, the kinetics of surfactant has been interpreted based on its function, as a component of the innate immunity and considering its role against tissue destruction. The peak of surfactant occurs before the peak of IFN- γ and TNF and its production is sustained as a consequence of cumulative infiltration of the lung parenchyma,^{27,28,68} causing constant injury to this tissue. In this model, the presence of FM is a consequence of the accumulation of parenchymal debris, surfactant and dead *M. tuberculosis* cells.

Note that if latent bacilli remain in the macrophage initially infected, which has been activated




Figure 1 Evolution model in experimental murine TB, focusing on the local presence of growing/dead bacilli; surfactant, IFN- γ and TNF production; and presence of FM. Continuous and dashed lines mark the peak and the base of growing bacilli. Dotted lines represent a cycle in the evolution in the chronic phase.

and has destroyed most bacilli, and it becomes a FM, it is reasonable to assume that, with time, low pH will be neutralized and the bacilli will re-grow when FM are at the periphery of the granuloma. However, if these infected macrophages become apoptotic or necrotized in the center of the granuloma, what happens when the latent bacilli is phagocytized by new macrophages? These bacilli are metabolically inactive and they cannot avoid the phagosome-lysosome fusion, as it requires a strong metabolic effort.⁶⁹ These latent bacilli are then considered "dead bacilli" and must face, once again, a low pH that will further prolong their latent state until stressful conditions disappear. This hypothesis may also explain why very few bacilli remain in FM and why so few are drained to the periphery where they finally re-grow. Interestingly, in both situations the antigens of the latent bacilli can be easily processed due their "dead

like" status,^{70,71} and if they are presented inside apoptotic vesicles, they would enhance antigen presentation through MHC I and CD1 molecules.⁷² Paradoxically, latent bacilli might trigger a specific immunity. Why does this not happen? The answer may be "due to local immunosuppression induced by FM" or "because the macrophages harboring them do not reach the lymph nodes to present the antigens, as this is not their role".

Finally, we must also consider the hypothesis that FM cannot produce mature endosomes and induce stress to bacilli, due to having too much material to process, thus encouraging bacillary regrowth at the periphery.

In fact, the presence of these FM is crucial in the murine model, as they allow continuous infiltration of the pulmonary parenchyma during the chronic phase of the infection.^{26,27} However, this phenomenon seems to be limited in bigger hosts, such as guinea pigs⁷³ or humans,⁷⁴ where the host triggers a strong inflammatory response at the beginning of the infection, inducing IN and quickly surrounding the granuloma with a fibrotic mantle. Nevertheless, these foamy cells have also been observed inside the granuloma harboring single bacilli.

All these data support the hypothesis that latent infection in humans is sustained by a static population in the necrotic tissues and by a constant reactivation of latent bacilli phagocytized by macrophages trying to reabsorb the necrotic tissues. *M. tuberculosis* recognizes the absence of stressful conditions by modulating their gene-expression depending on external conditions (i.e. icl production is triggered with acid pH)⁷⁵ and must also detect when the adverse conditions disappear (i.e. when phagocytized by FM) and thus when they can start growing.

The very low metabolic activity of *M. tuberculosis*⁷⁶ also favors their survival. These bacilli may reactivate far from the initial infection focus, away from the presence of effector T cells, and inside the alveolar space where, after growing and destroying the infected macrophages, they can easily disseminate to be phagocytized by other naïve alveolar macrophages and reinitiate infection. The focus of the immunological response is on growing bacilli, which pool is constantly regenerated; in contrast, a response against latent bacilli, if it is ever triggered, remains relatively weak.

As represented in Fig. 2A, the suggested scenario of LTBI includes a static population of latent bacilli that periodically re-grows at different sites of the parenchyma. For a bacillus in this context, reaching a convenient site for growth is crucial (e.g., the apical zones of the lung with high oxygen pressure to induce a large granuloma and a cavern).⁷⁷




Figure 2 Mathematical approach to latency in TB based on the constant reactivation of latent bacilli. There is an acute phase where bacilli reach maximum concentration after 20 days of constant growth that lasts until the immune response is triggered and 99% of the bacillary bulk is destroyed (A). This reaction originates from 0.1% of latent bacilli in necrotic tissue. The remaining 1% of bacilli in macrophages re-grow after a resting period of 20 days, when once again 99% are destroyed, originating another 0.1% of latent bacilli in a necrotic tissue. This dynamic continues until equilibrium is reached at the tolerance threshold in humans of $2 \log_{10}$. The number of bacilli in necrotic tissue decreases while the resting period between reactivations increases proportionally to historical data⁸¹ of untreated tuberculosis-infected household contacts. This data suggests that the disease occurs at a rate of 0.74% per year in years 1 and 2; 0.31% per year in years 3–5; and 0.16% per year in years 6 and 7. (B) shows the end of constant re-growing with chemotherapy and the elimination of latent bacilli from necrotic tissue calculated in relation to the protection obtained with several periods of treatment with INH.¹²⁹ The number of bacilli inside macrophages is indicated in red, whereas the bacillary number in necrotic tissues is in gray. The time of chemotherapy is presented in orange.

As a consequence of all the above, the strategy of inducing a strong Th1 response is not relevant for designing an immunotherapeutic strategy against LTBI, especially if we take into account that humans, who are the hosts that manage to control *M. tuberculosis* infection most effectively, trigger a Th1–Th2 response. Th1 response kills growing bacilli whereas Th2 “walls off” latent bacilli, the latter being responsible for granuloma fibrosis,^{78,79}

together with the presence of TGF- β ,⁸⁰ a Th3 response. However, it has been suggested that TGF- β is the only factor required for fibrosis of the granulomas,⁸⁰ i.e. to ensure that latent bacilli do not escape. In this scenario also, a “pure” Th1 response, such as occurs in mice, does not “close” the granuloma sufficiently and therefore allows constant dissemination of the infection.^{26,27} Even more, as NO local production is paramount in chronic phase granulomas and inhibits both Th1 and Th2 responses⁸⁰ it is nonsense to increase any of them as it will be useless.

Interestingly, histopathology studies on human TB lesions have demonstrated that the presence of IL-4 may not be an indicator of poor prognosis in such patients but rather may be an integral feature of tuberculous granuloma formation with a role in controlling tissue damage.⁸¹ In the same study, those patients exhibiting the highest percentage of TNF-positive granulomas also have IL-4-positive granulomas and a lower percentage of granulomas with caseous necrosis.

Why does conventional chemotherapy of LTBI need such a long period of treatment?

According to the field-work carried out by Comstock,⁸² the gold-standard treatment for LTBI is the administration of INH for 9 months.⁸ Interestingly, the study of early bactericidal activity (EBA) of INH in patients with pulmonary TB shows that the highest bactericidal activity is achieved within the first 2 days of treatment (with a $0.7 \log_{10}$ reduction).⁸³ Essentially, the highest bactericidal effect of INH occurs within the first 15 days post administration. Therefore, why is such a long treatment period required? This is because INH, as most bactericidal drugs, is only effective against actively growing bacilli. In fact, in the case of cavitary TB, INH is effective because there is an important extracellular population with many actively growing bacilli.^{84,85}

The long period of chemotherapy required in LTBI treatment may be explained by the ability of chemotherapy to stop constant regrowth of bacilli (Fig. 2B): the lack of growing bacilli reduces local inflammatory and immunological responses^{55,86} allowing reabsorption of the necrotic debris, surfactant and dead bacilli, thus significantly reducing the presence of FM and latent bacilli. Considering that this decrease in local immune responses facilitates future re-growing of latent bacilli if these bacilli are not completely removed,

it is crucial to maintain long chemotherapy periods so as to allow total removal of latent bacilli from the pulmonary parenchyma.

What does RUTI do?

The design of RUTI

RUTI was designed to fill the immunological gap left by short-term therapy for *M. tuberculosis* infection. In fact, our group demonstrated in previous investigations and in different experimental models of TB in mice that *M. tuberculosis* grew again after short-term chemotherapy, although this was not followed by an immediate stimulation of immunity. Moreover, this delayed immune stimulation was only triggered when the bacterial load reached a value of $4 \log_{10}$ (after a period of 2 months),⁶⁵ which had clear implications for the "old issue" of "tolerance" of mice to larger bacillary exposure than humans, and the need for more bacilli to boost immunity.²⁰ The original idea on introducing RUTI, therefore, was to "boost" the immunological response against *M. tuberculosis* that already existed in the host.

RUTI was also designed to trigger a new immunological response against antigens of the latent bacilli, i.e. the so-called "structural" antigens⁸⁷ as well as those associated to stress responses. Protective immunity arises against antigens that are actively released by growing bacilli⁸⁸ and it is likely that the "focus" of the immunological response only on growing bacilli allows nonactive bacilli to remain "invisible" to the specific immunity of the host.

RUTI is made with bacilli grown under the stressful conditions of starvation, low pO_2 and low pH, conditions achieved gradually by culturing on solid media.^{89,90} Progress to stressful conditions (e.g., low pO_2) has been shown to "prepare" the bacilli for even more stressful conditions (e.g., strict anaerobiosis),³ while progressive starvation is known to lead to stationary growth in old cultures in which slow metabolism makes bacilli more resistant to stress, as in the chronic phase of the murine infection.¹⁵ In summary, bacilli used to make RUTI are subjected to conditions that are probably found in the granuloma of hosts with active immunity: a low pO_2 in fibrotic structure of the granuloma and the low pH and starving conditions inside the phagolysosome of the activated macrophage.

The choice of fragmentation of the bacilli to make RUTI was to allow optimal presentation of cell wall antigens, as was the choice of composition

into liposomes.⁹¹ The average diameter of these fragments, which is 0.1 μm , allows the antigens in the cell wall to be well presented and thus provide an easier recognition of latent bacilli. Moreover, it is well known that the cell wall of *M. tuberculosis* has adjuvant properties⁹² that ensure the induction of an immunological response without further adjuvant measures. In addition, the induction of a polyantigenic response is postulated to help recognize latent bacilli.

Another relevant feature of RUTI is the "detoxification" of the cell fragments obtained. In previous experiments, our findings supported the hypothesis that the characteristic IN in granulomas of *M. tuberculosis* was induced nonspecifically by endotoxin-like molecules, essentially glycolipids located in the outermost layer of the cell wall²⁰ instead of being induced by a specific immunological response such as delayed type hypersensitivity (DTH).⁵³ Our hypothesis arose from previous work by the group of G.A.W. Rook, suggesting that IN induced by the "Koch phenomenon" resembles a local "Schwartzman reaction".¹⁹ This necrosis is not usually seen in murine experimental models, maybe due to the relative "tolerance" of these small hosts to *M. tuberculosis* antigens. For the response to infection in mice to behave like other, larger, mammals that spontaneously develop this necrosis,¹⁸ mice would require a higher amount of endotoxin-like molecules.²⁰ Therefore, to avoid the potential risk of developing a Koch phenomenon caused by a therapeutic vaccine against LTBI^{94,95} we decided to remove endotoxin-like molecules from the surface of the fragments using Triton X-114,⁹⁶ a detergent that minimizes the denaturation of antigenic proteins. Finally, we also removed the lipidic phase to enhance the presentation of those "hidden" antigens by the outer coat and to increase the range of the immunological response.

The protection mechanisms of RUTI

By using a western blot technique, we observed that the inoculation of 3 doses of RUTI (of 185 μg each) 2 weeks apart, after chemotherapy, induced a strong polyantigenic response, triggering a strong Th1-Th2 immunity against at least 13 known *M. tuberculosis* antigens, as well as a Th3 response.⁸⁷ In addition, studies on the cellular immunity induced by 2 doses of RUTI (245 μg 3 weeks a part) and compared with the inoculation of BCG in mice previously treated with chemotherapy, revealed that both inoculation of BCG or RUTI induced a 10-fold increase in the CD4 IFN- γ + population induced by PPD stimulation. Interestingly, RUTI also enhanced ten times the

CD8 IFN- γ population (Fig. 3), whereas this increase was not detected with BCG⁹⁷ which induced no protection, a difference already found by other authors.⁹⁸ This difference may explain the improved effectiveness of RUTI, since the CD8 IFN- γ population is crucial for the control of latent bacilli.⁹⁹ Additionally, antigenic differences between BCG and *M. tuberculosis* also help to explain differences in protection,¹⁰⁰ which was another important factor for the design of RUTI.

Although the exact mechanism by which RUTI increases the CD8 IFN- γ population in the lungs remains to be elucidated, its delivery as liposomes appears crucial; alternatively, the induction of apoptosis in macrophages that phagocyte RUTI,¹⁰¹ may also favor a CD8 response.¹⁰²

We were surprised to find that polyclonal antibodies obtained after RUTI administration provided protection against *M. tuberculosis* reactivation after chemotherapy in SCID mice.¹⁰³ In these experiments, we allowed aerosol infection to progress for 3 weeks, at which point chemotherapy with INH and rifampicin was administered for 5 weeks. After chemotherapy, two experimental groups were defined by the inoculation of serum obtained from infected immunocompetent mice treated with chemotherapy and RUTI (serum-therapy group), or the inoculation of serum from noninfected untreated immunocompetent mice (control group). After 2 weeks, necropsies revealed a significant difference between both groups: the serum-therapy group reflected a weaker bacillary




Figure 3 Evolution of TCD4+ and TCD8+ IFN γ cells from lungs in mice treated with chemotherapy from weeks 6 to 14, and treated with 2 subcutaneous (s.c.) inoculations of RUTI (245 μ g) at weeks 14 and 17; 1 s.c. inoculation of BCG (10e6 CFUs) at week 14 or 1 s.c. of empty liposomes (control)—white, gray and black symbols, respectively. The results are given as mean values with standard deviations obtained from 4 mice for each time point. Differences with control were significant when marked with * for $p < 0.05$.⁹⁷

reactivation (Fig. 4), 100 times less than the control, and a decreased granulomatous infiltration in the lungs (3 times less than the control). In fact, mice from the serum-therapy group developed fewer abscesses. These data support the notion that IgG antibodies are also able to control dissemination of the infection in the pulmonary parenchyma, as was earlier suggested from experiments of infection of bacilli pre-coated with specific IgG,¹⁰⁴ or by inducing active IgA production.¹⁰⁵ Interestingly, it has been recently shown that inoculation of nonspecific IgG also increases the effectiveness of chemotherapy when administered therapeutically.¹⁰⁶ Furthermore, a strong response of specific antibodies against lipoarabinomannan¹⁰⁷ and Ag85¹⁰⁸ were also associated with better prognosis in patients with active TB, further supporting the current view that mere production of IFN- γ is insufficient for induction of protection against TB, as reflected in the paradoxical protection achieved by *Cynomolgus macaca* with BCG vaccination, which could not be linked to the production of IFN- γ .¹⁰⁹

A combined cell/antibody-mediated immunity and combined Th1/Th2/Th3 immunity is thought to provide the protection elicited by RUTI. This type of response is coherent with the concept of global immunity against latent bacilli, with an aggressive Th1 cellular response probably mediated by CD8+ T cells; Th2 and Th3 responses that wall off the granuloma^{79,80,110}; and an antibody Th1/Th2




Figure 4 Control of CFUs after serum-therapy in the lung of SCID mice. After infection, mice were treated with INH+RIF from week 3–8 (in gray), and treated with 4 intraperitoneal (i.p.) inoculations of serum (hyperimmune serum, HS) from mice treated with a short period chemotherapy and RUTI (in white) or from normal noninfected mice (in black). The results are given as mean values with standard deviations obtained from 4 mice for each time point (apart from week 19, where 10 mice were treated with immune serum and 11 mice were given normal serum). Differences with control were significant when marked with * for $p < 0.05$.¹⁰³

production that neutralizes the extracellular bacilli that escape through the alveolar spaces.

These conclusions do not agree with the most common hypothesis suggesting that immunity against *M. tuberculosis* infection must be induced by a Th1 response, whereas Th2 responses are detrimental. This hypothesis is based on the Th1/Th2 response triggered by TB patients compared with the responses seen in patients with LTBI, who are thought to avoid reactivation of their latent infection.¹¹¹ In this regard, since Th2 response plays a relevant role in the immunopathology of TB lesions in controlling and reclosing a large lesion (i.e. a cavern) by building a strong fibrotic mantle around it, a complete absence of any Th2 response would be surprising. In any case, since most of these findings are incidental, we consider that the hypothesis suffers from a "chicken and egg" problem: are these patients suffering TB because of Th2 polarization, or do they develop a Th2/Th3 response to face the disease?

Another interesting point is the lack of efficacy of BCG vaccination in newborn babies in the Third World due to the lack of a strong Th1 response. This seems to be caused by the in utero sensitization to filariae, which results in a Th2 bias, leading to a Th1/Th2 response instead of a stronger Th1 response as observed against PPD-driven IFN- γ production.¹¹² On the other hand, the immunological environment at the fetomaternal interface is Th2 dominated in order to protect the fetoplacental unit, and at this age the induction of a Th2 immunological response is generalized.¹¹³ Furthermore, experimental mice models do not support this hypothesis: no difference in either protection or in the progression of *M. tuberculosis* infection has been found after vaccination with different doses of BCG that induced either pure Th1 or mixed Th1/Th2 responses.¹¹⁴ Even more so, no differences in the evolution of *M. tuberculosis* infection could be demonstrated in IL-4, IL-4 plus IL-13 KO,¹¹⁵ and IL-10 KO mice compared with wild-type mice.¹¹⁶ Finally, long-term chronic murine TB in the lungs was not influenced by the absence of B lymphocytes or IL-4.¹¹⁷

The role of the Th3 response triggered by RUTI must be clarified. It is possible that Th3 plays an important role beyond the final fibrosis of the granulomas through the action of TGF- β .^{79,80,111} In fact, immunotherapy with DNA encoding for stress proteins like hsp 65 has proven effective against *M. tuberculosis* infection when combined with chemotherapy.^{118,119} It is widely accepted that these proteins induce regulatory T cells that can suppress autoimmunity induced by Th1 or Th2 responses, thus counterbalancing the immune response.¹²⁰ In

this regard, these proteins may help to "synchronize" the immune response (i.e. activating the infected macrophages or walling off the granulomas) rather than just inducing a strong Th1 response¹²¹ or reducing the Th2 response, similar to the postulated mechanism of *Mycobacterium vaccae* immunotherapy.¹²²

Why is previous short-term chemotherapy still necessary before LTBI therapeutic vaccination?

At this point, it is very important to study LTBI in human patients, because we currently ignore which bacillary population the lesions harbor. Are most of these bacilli actively growing or are they latent? And which is the relative proportion of these populations? The presence of heterogeneous populations in a lesion may explain why a short period of chemotherapy (e.g. 4 weeks), which could "harmonize" or "standardize" the bacillary population in all patients toward a latent population, is advantageous for therapy.

Furthermore, this short period of chemotherapy also allows a decrease in the immunological constant boost against growing bacilli and removes FM (Fig. 5) and thus the source of local immunosuppression. Moreover, chemotherapy in patients with LTBI has also been associated with the increase of Th1 specific effector cells in peripheral blood within the first 4 weeks of LTBI conventional chemotherapy (9 months of INH). This rise in Th1 effector cells arises from antigen presentation and the release of effector T cells from the infected sites.¹²³ These data also support the hypothesis that local changes in the granuloma favour recognition of latent bacilli. Chemotherapy also increases reabsorption of the lesion, therefore reducing the inflammatory response in the lungs,^{65,86} reducing the chance that the therapeutic vaccine will induce a Koch phenomenon, because the infected site will no longer be a "prepared site".

In conclusion, the need for chemotherapy indicates that once latent bacilli are induced, vaccination is useless because these bacilli remain invisible to the immune system. Moreover, even if the host's immunity is already prepared to control infection, it cannot prevent the reactivation of these cells in a site which is privileged for the bacilli (such as the pulmonary apex), thus being unable to prevent the induction of pulmonary TB. Therefore, it is possible that chemotherapy allows the presentation of latent bacilli to the host immunity by "rediscovering" their presence.




Figure 5 Effects of 8-week chemotherapy on the structure of granulomas. Note the lack of FM in the periphery of treated mice (B) compared with mice before starting chemotherapy (A), at week 8 post-aerosol infection. Slides were stained with hematoxylin-eosin. Original amplification is 400x (data not published).

How has the effectiveness of RUTI been assessed?

The research of new drugs and vaccines against TB is especially difficult because no direct correlation exists between the results obtained in commonly used experimental models and what really happens in humans. For instance, testing new prophylactic vaccines requires an efficacy at least similar to that obtained with BCG vaccination, which reduces bacterial concentration in mouse lungs by 1 log₁₀ at 3 weeks after infection compared to nonvaccinated animals and allows infected guinea pigs to survive for up to 30 weeks instead of the 14 weeks usually seen in nonvaccinated animals.¹²⁴ Overall, prophylactic vaccines do not provide any prophylaxis but improve control of the infection, although they do not prevent death of infected animals as a result of TB development. The lack of clear correlation between effectiveness of vaccines in animal models and in humans means that the validation of new therapies in experimental models must be interpreted with caution. For example, in LTBI therapy, the gold standard treatment ensures a 90% efficacy against LTBI reactivation in humans⁸² but at most it only achieves a 10% efficacy in mice.¹²⁵

Another striking and relevant question already discussed above relates to the type of experimental model that needs to be used for testing the efficacy of a new therapeutic vaccine, with the aim of mimicking what happens in humans. The Cornell




Figure 6 Bactericidal activity of RUTI in the lung of C57BL/6 mice. After infection, mice were treated with INH+RIF from week 9–17 (in gray), and with 3 subcutaneous (s.c.) inoculations of RUTI (185 µg per inoculation) at weeks 17, 19 and 21 (in white) or empty liposomes (in black). The results are given as mean values with standard deviations obtained from 4 to 6 mice for each time point. Differences with control were significant when marked with * for $p < 0.05$ (modified from⁸⁷).

model does not appear very appropriate because it is not clear if persistent or latent bacilli are present, and no “complete” granulomas and growing bacilli are detected at the onset of treatment. Thus it does not reflect the conditions of human LTBI. Instead, we chose chronic infection in mice as a starting point. Moreover, the “tolerance” shown by mice to *M. tuberculosis* infection

may underestimate new treatments, as the host does not display a strong inflammatory response against the bacilli, suggesting that evaluating the reduction of bacillary bulk and its control after chemotherapy should be the final target instead of sterilization. It is relevant that initial experiments showed that RUTI significantly reduced the bacillary bulk (Fig. 6)⁸⁷ and maintained this control for a long time, at least for up to 11 weeks after the last RUTI inoculation.¹²⁶

Concerning the "tolerance" phenomenon discussed above, we decided to run new experiments with guinea pigs instead of mice. The rationale for this decision was based on the hypothesis that the bigger the host, the stronger the inflammatory response against *M. tuberculosis*, because more parenchyma can be destroyed in larger animals to

stop bacillary growth (assuming that the size of immune cells is similar in all mammals). Fig. 7 exemplifies this idea by comparing the volume of a small human TB cavern with the total volumes of different mammals, and shows that a mouse will never develop such a lesion, as it represents its total volume. We thus started working with the guinea pig using a more "humanized", short chemotherapy regimen (4 weeks with INH and rifampicin), as well as a more virulent *M. tuberculosis* strain (H37Rv Pasteur). Histopathological analysis 4 weeks after infection showed that guinea pigs developed a structured and defined granuloma, with strong outermost fibrosis and IN; few acid fast-bacilli were detected, localized only in the periphery of the granuloma and inside FM (Fig. 8). In contrast, at this same time point, mice only




Figure 7 Comparison of different hosts according to their weight. The volume of a TB cavern weighing 25 g is shown in red.




Figure 8 Comparison of lesions in guinea pigs (A-D) and mice (E-H) at week 4 post-aerosol infection. Pictures A, B, E and F show the structure of the granuloma stained with haematoxylin-eosin. Note the highly organized guinea pig granuloma, the presence of a central necrotic tissue surrounded by a mantle of fibrotic tissue and an outermost layer dominated by lymphocytes. In contrast, the granuloma of mice is just a mixture of PMNs, macrophages and some lymphocytes with no apparent organization. Pictures C, D, G and H show the result of Ziehl Neelsen staining in these granulomas. Acid-fast bacilli are scarce inside FM included in the fibrotic mantle (C), and inside the necrotic center (D); on the contrary, acid fast bacilli can be easily seen in mice granuloma (G and H).

developed a tiny pre-granuloma full of acid-fast bacilli, with no outer fibrotic content, thus leaving more time for further pulmonary dissemination. In fact, bacillary counts were higher in mice than in guinea pigs (1 log₁₀ more),¹²⁷ which agree with previous reports.¹²⁸ In this context, administration of 3 doses of RUTI (180 µg) at weeks 8, 10 and 14




Figure 9 Bactericidal activity of RUTI in the lung of guinea pigs. After infection, animals were treated with INH+RIF from week 4–8 (in gray), and with 3 subcutaneous (s.c.) inoculations of RUTI (185 µg per inoculation) at weeks 8, 10 and 14 (in white) or empty liposomes (in black). The results are given as mean values with standard deviations obtained from 8 animals for each time point. Differences with control were significant when marked with * for $p < 0.05$.¹²⁷

after shorter chemotherapy than in mice experiments (between weeks 4 and 8) significantly decreased the bacillary load at week 16 (at the time of necropsy) even when bacillary bulk in control guinea pigs did not increase (Fig. 9). In contrast, bacillary counts in control mice increased by 2 log₁₀ when the same *M. tuberculosis* strain was used.⁹⁷

Note that control of the bacillary count in guinea pigs requires a tremendous inflammatory effort that finally kills the host faster than it kills mice. Therefore, we cannot assume that mice are more resistant to *M. tuberculosis* infection than guinea pigs, but instead, we assume that mice are more "tolerant" to these bacilli, allowing an abundance of bacilli in their lungs by triggering a weaker inflammatory response. This tolerance allows mice to survive longer to *M. tuberculosis* infection, but in the end the bacilli also kill the host due to constant dissemination throughout their lungs.^{26,27,68} However, it is obvious that the evolution of infection is not equivalent in guinea pigs and in human hosts because the latter control bacillary progression better by walling them off in the granulomas. The formation of granulomas in humans will also allow administration of weaker chemotherapy (e.g. INH alone) rather than the combination of INH and rifampicin required for controlling infection in guinea pigs.

Table 1. Properties of the LTBI.

A. The nature of latent bacilli

1. Mycobacterium tuberculosis has a innate slow growth-rate.
2. Once submitted to stress, bacilli slow metabolism to near-zero activity, in which situation the bacilli can resist stressful environments.
3. A relevant capacity to survive in necrotic tissue.
4. Bacilli can grow at the periphery of the granulomas once the stress has resumed.

B. The host immunological response

1. The host develop active immunity largely against growing bacilli.
2. CD8 T cells may play a relevant role in the control of latent bacilli.

C. The role of foamy macrophages

1. Are a consequence of the accumulation of necrotic debris, surfactant and dead *M. tuberculosis* cells.
2. Have a decreased ability for presenting antigens.
3. Suppress effector T cells that try to activate them.
4. Harbour latent bacilli.
5. Represent the outermost layer of the granuloma.
6. Render the induction of a specific immunological response against latent bacilli useless.

Key aspects for the destruction of *M. tuberculosis* latent bacilli

1. Removal of the outermost layer of foamy macrophages that exert local immunosuppression.
2. Induction of a polyclonal immunological response not only against antigens of actively growing bacilli, but also against structural antigens.

Regarding the possible toxicity of RUTI, in both experiments with mice and guinea pigs, only a local transient inflammatory response at the site of inoculation was found. No systemic toxicity (weight loss or increased granulomatous response) were detected.

The future

Based on current data, new experiments are being carried out to gain further understanding of all the mechanisms involved in the protective benefits of RUTI. These experiments include more "humanized" models with larger mammalian hosts. In this regard, we have started some field experiments with naturally infected goats and experimental models such as mini-pigs. Our aim is to use hosts with a volume more comparable to humans than models used hitherto, to determine the protective effects of RUTI and also to confirm lack of toxicity, because larger hosts are more likely to develop greater inflammatory responses and the Koch phenomenon.

In conclusion, we expect to achieve a better chemotherapeutic treatment of LTBI patients, by administering INH for a short period of time, i.e. 4 weeks, with only 2 doses of RUTI; this improved regimen is also expected to ameliorate treatment compliance. (Table 1)

Acknowledgements

I'm in debt with Rajko Reljic, Juraj Ivanyi and Irene Garcia-Gabay for their contributions to the paper.

References

- Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1994;38:2054-8.
- Wayne LG, Sohaskey CD. Nonreplicating persistence of *Mycobacterium tuberculosis*. *Annu Rev Microbiol* 2001;55:139-63.
- Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of *Mycobacterium tuberculosis* to survival under anaerobic conditions. *Infect Immun* 1982;37:1042-9.
- Mochizuki M. Kinetics of oxygen and carbon dioxide reactions. Crystal RG, West JB, et al., editors. *The lung: scientific foundations*, vol. 5.3.2.4. New York: Raven Press Ltd; 1991. p. 1241-52.
- Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. *J Exp Med* 1993;178:2243-7.
- Gil O, Quirado E, Gordillo S, et al. Intracranial granuloma necrosis in lungs of mice infected by aerosol with

- Mycobacterium tuberculosis* is related to bacterial load rather than to any one cytokine or T cell type. *Micr Infect*. Available online 17 January 2006.
- McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence I The capacity of tubercle bacilli to survive sterilization in mouse tissues. *J Exp Med* 1966;123:445-68.
 - American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *Am J Respir Crit Care Med* 2000;161:S221-47.
 - Lucas SB. Histopathology. Davies PDO, editor. *Clinical tuberculosis*, vol. 8. London: Chapman & Hall; 1998. p. 113-27.
 - Gomez JE, McKinney JD, editors. M. tuberculosis persistence latency and drug tolerance. *Tuberculosis (Edinburgh)* 2004;84:29-44.
 - Orme IM. The latent tuberculosis bacillus I'll let you know if I ever meet one. *Int J Tuberc Lung Dis* 2001;5:589-93.
 - Wallis RS, Patil S, Cheon SH, et al. Drug tolerance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 1999;43:2600-6.
 - Shleeva MO, Bagryanay K, Telkov MV, et al. Formation and resuscitation of "non-culturable" cells of *Rhodococcus rhodochrous* and *Mycobacterium tuberculosis* in prolonged stationary phase. *Microbiology* 2002;148:1581-91.
 - Kell DB, Young M. Bacterial dormancy and culturability: the role of autocrine growth factors. *Curr Opin Microbiol* 2000;3:238-43.
 - Wallace JG. The heat resistance of tubercle bacilli in the lungs of infected mice. *Am Rev Respir Dis* 1961;83:866-71.
 - Muñoz-Elias EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD. Replication dynamics of *Mycobacterium tuberculosis* in chronically infected mice. *Infect Immun* 2005;73:546-51.
 - Lazarevic V, Nolt D, Flynn JL. Long-term control of *Mycobacterium tuberculosis* infection is mediated by dynamic immune responses. *J Immunol* 2005;175:1107-17.
 - Thoen CO. Tuberculosis in wild and domestic mammals. Bloom BR, editor. *Tuberculosis pathogenesis protection and control*, vol. 11. Washington, DC: ASM Press; 1994. p. 157-64.
 - Rook GA, Attiyah R. Cytokines and the Koch phenomenon. *Tubercle* 1991;72:13-20.
 - Cardona PJ, Llatjos R, Gordillo S, et al. Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with *Mycobacterium tuberculosis*. *Scand J Immunol* 2001;53:65-71.
 - Ryll R, Kumazawa Y, Yano I. Immunological properties of trehalose dimycolate cord factor and other mycolic acid-containing glycolipids—a review. *Microbiol Immunol* 2001;45:801-11.
 - Indrigo J, Hunter Jr RL, Actor JK. Cord factor trehalose 66'-dimycolate TDM mediates trafficking events during mycobacterial infection of murine macrophages. *Microbiology* 2003;149:2049-59.
 - Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001;9:93-129.
 - Orme IM, editor. The mouse as a useful model of tuberculosis. *Tuberculosis (Edinburgh)* 2003;83:112-5.
 - North RJ, Jung YJ. Immunity to tuberculosis. *Annu Rev Immunol* 2004;22:599-623.
 - Cardona PJ, Llatjos R, Gordillo S, et al. Evolution of granulomas in lungs of mice infected aerogenically with *Mycobacterium tuberculosis*. *Scand J Immunol* 2000;52:156-63.


27. Cardona PJ, Gordillo S, Diaz J, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with *Mycobacterium tuberculosis*. *Infect Immun* 2003;71:5845-54.
28. Green GM, Burlington VT. Alveolobronchiolar transport mechanisms. *Arch Intern Med* 1973;131:109-14.
29. Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J. The *Mycobacterium tuberculosis* cell wall component mycolic acid elicits pathogen-associated host innate immune responses. *Eur J Immunol* 2005;35:890-900.
30. Eriksson U, Eggermann U, Bihl MP, et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. *J Immunol* 2005;175:2715-20.
31. Mills CD. Molecular basis of "suppressor" macrophages Arginine metabolism via the nitric oxide synthetase pathway. *J Immunol* 1991;146:2719-23.
32. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. *J Immunol* 1998;160:5729-34.
33. Nabeshima S, Nemoto M, Matsuzaki G, et al. T-Cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with *Mycobacterium tuberculosis*. *Infect Immun* 1999;67:3221-6.
34. Chan ED, Chan J, Schlager NW. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. *Am J Respir Cell Mol Biol* 2001;25:606-12.
35. Flynn JL, Scanga CA, Tanaka KE, Chan J. Effects of aminoguanidine on latent murine tuberculosis. *J Immunol* 1998;160:1796-803.
36. Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF- α . *Am J Physiol* 1991;261:C634-41.
37. Nussler AK, Di Silvio M, Billiar TR, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. *J Exp Med* 1992;176:261-4.
38. Chu SC, Marks-Konczalka J, Wu HP, Banks TC, Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. *Biochem Biophys Res Commun* 1998;248:871-8.
39. Kolb JP, Paul-Eugene N, Damais C, Yamaoka K, Drapier JC, Dugas B. Interleukin-4 stimulates cGMP production by IFN- γ -activated human monocytes. Involvement of the nitric oxide synthase pathway. *J Biol Chem* 1994;269:9811-6.
40. Guo FH, Uctiani K, Haque SJ, et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. *J Clin Invest* 1997;100:829-38.
41. Eigler A, Moeller J, Endres S. Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. *J Immunol* 1995;154:4048-54.
42. Eriksson U, Eggermann U, Bihl MP, et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. *J Immunol* 2005;175:2715-20.
43. Cooper AM, Adams LB, Dalton DK, Appelberg R, Ehlers S. IFN- γ and NO in mycobacterial disease: new jobs for old hands. *Trends Microbiol* 2002;10:221-6.
44. Hernandez-Pando R, Schon T, Orozco EH, Serafin J, Estrada-Garcia I. Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. *Exp Toxicol Pathol* 2001;53:257-65.
45. Yu K, Mitchell C, King Y, Magliozzo RS, Bloom BR, Chan J. Toxicity of nitrogen oxides and related oxidants on mycobacteria: *M. tuberculosis* is resistant to peroxynitrite anion. *Tuber Lung Dis* 1999;79:191-8.
46. Robinson VK, Sato E, Nelson DK, Camm SL, Robbins RA, Hoyt JC. Peroxynitrite inhibits inducible (type 2) nitric oxide synthase in murine lung epithelial cells in vitro. *Free Radic Biol Med* 2001;30:986-91.
47. Moriwaiki H, Kume N, Kataoka H, et al. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF- α . *FEBS Lett* 1998;440:29-32.
48. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. *Am J Physiol Heart Circ Physiol* 2004;287:H782-90.
49. Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. *J Biol Chem* 2002;277:34573-80.
50. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. *Nat Med* 2002;8:1235-42.
51. Burleigh ME, Babaei VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. *Circulation* 2002;105:1816-23.
52. Wright JR. Immunomodulatory functions of surfactant. *Physiol Rev* 1997;77:931-62.
53. Lian X, Yan C, Yang L, Xu Y, Du H. Lysosomal acid lipase deficiency causes respiratory inflammation and destruction in the lung. *Am J Physiol Lung Cell Mol Physiol* 2004;286:L801-7.
54. Kramer BW, Jowe AH, Ikegami M. Exogenous surfactant changes the phenotype of alveolar macrophages in mice. *Am J Physiol Lung Cell Mol Physiol* 2001;280:L689-94.
55. Chan ED, Morris KR, Belisle JT, et al. Induction of inducible nitric oxide synthase-NO $^+$ by liparabinomannan of *Mycobacterium tuberculosis* is mediated by MEK1-ERK, MKK7-JNK, and NF- κ B signaling pathways. *Infect Immun* 2001;69:2001-10.
56. Rhoades ER, Orme IM. Susceptibility of a panel of virulent strains of *Mycobacterium tuberculosis* to reactive nitrogen intermediates. *Infect Immun* 1997;65:1189-95.
57. Brugmann WB, Firmani MA. Low concentrations of nitric oxide exert a hormetic effect on *Mycobacterium tuberculosis* in vitro. *J Clin Microbiol* 2005;43:4844-6.
58. Ciccone R, Mariani F, Cavone A, et al. Inhibitory effect of NO-releasing Ciprofloxacin (NCX 976) on *Mycobacterium tuberculosis* survival. *Antimicrob Agents Chemother* 2003;43:2299-305.
59. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a *Mycobacterium tuberculosis* dormancy program. *J Exp Med* 2003;198:705-12.
60. Schnappinger D, Eht S, Voskuil MI, et al. Transcriptional Adaptation of *Mycobacterium tuberculosis* within Macrophages: Insights into the Phagosomal environment. *J Exp Med* 2003;198:693-700.
61. Ohno H, Zhu G, Mohan VP, et al. The effects of reactive nitrogen intermediates on gene expression in *Mycobacterium tuberculosis*. *Cell Microbiol* 2003;5:637-45.
62. Darwin KH, Eht S, Gutierrez-Ramos JC, Welch N, Nathan CF. The proteasome of *Mycobacterium tuberculosis* is

- required for resistance to nitric oxide. *Science* 2003;302:1963-9.
63. Hernandez-Pando R, Orozco H, Arringa K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha tumour necrosis factor-alpha and transforming growth factor-beta during the course of experimental pulmonary tuberculosis. *Immunology* 1997;90:607-17.
 64. Ordway D, Henao-Tamayo M, Orme IM, Gonzalez-Juarrero M. Foamy macrophages within lung granulomas of mice infected with *Mycobacterium tuberculosis* express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. *J Immunol* 2005;175:3873-81.
 65. Cardona PJ, Julian E, Valles X, et al. Production of antibodies against glycolipids from the *Mycobacterium tuberculosis* cell wall in aerosol murine models of tuberculosis. *Scand J Immunol* 2002;55:639-45.
 66. Shalit I, Horev-Azaria I, Fabian I, et al. Immunomodulatory and protective effects of moxifloxacin against *Candida albicans*-induced bronchopneumonia in mice injected with cyclophosphamide. *Antimicrob Agents Chemother* 2002;46:2442-9.
 67. Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H. Moxifloxacin inhibits cytokine-induced MAP kinase and NF-kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. *J Antimicrob Chemother* 2005;55:293-300.
 68. Dunn PL, North RJ. Virulence ranking of some *Mycobacterium tuberculosis* and *Mycobacterium bovis* strains according to their ability to multiply in the lungs induce lung pathology and cause mortality in mice. *Infect Immun* 1995;63:3428-37.
 69. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant *Mycobacterium bovis* bacille Calmette-Guerin mutants that secrete listeriolysin. *J Clin Invest* 2005;115:2472-9.
 70. Ramachandra L, Noss E, Boom WH, Harding CV. Processing of *Mycobacterium tuberculosis* antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation. *J Exp Med* 2001;194:1421-32.
 71. Ramachandra L, Smialek JL, Shank SS, Convery M, Boom WH, Harding CV. Phagosomal processing of *Mycobacterium tuberculosis* antigen 85B is modulated independently of mycobacterial viability and phagosome maturation. *Infect Immun* 2005;73:1097-105.
 72. Schaalbe UE, Winau P, Sieling PA, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. *Nat Med* 2003;9:1039-46.
 73. Turner OC, Basaraba RJ, Orme IM. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with *Mycobacterium tuberculosis*. *Infect Immun* 2003;71:864-71.
 74. Ulrichs T, Kosmiadi GA, Jorg S, et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. *J Infect Dis* 2005;192:89-97.
 75. Fisher MA, Plikaytis BB, Shinnick TM. Microarray analysis of the *Mycobacterium tuberculosis* transcriptional response to the acidic conditions found in phagosomes. *J Bacteriol* 2002;184:4025-32.
 76. Colston MJ, Cox RA. *Mycobacterial growth and dormancy*. Ratledge C, Dale J, editors. *Mycobacteria molecular biology and virulence*, vol. 11. London: Blackwell Science; 1999. p. 198-219.
 77. Cardona PJ, Ruiz-Manzano J. On the nature of *Mycobacterium tuberculosis*-latent bacilli. *Eur Respir J* 2004;24:1044-51.
 78. Rook GA, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. *Trends Immunol* 2004;25:483-8.
 79. Dheda K, Booth H, Huggett JR, Johnson MA, Zumla A, Rook GA. Lung Remodeling in Pulmonary Tuberculosis. *J Infect Dis* 2005;192:1201-9.
 80. Aung H, Toossi Z, McKenna SM, et al. Expression of transforming growth factor-beta but not tumor necrosis factor- α interferon- γ and interleukin-4 in granulomatous lung lesions in tuberculosis. *Tubercule Lung Dis* 2000;80:61-7.
 81. Fenhals G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Luky PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. *Infect Immun* 2000;68:2827-36.
 82. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? *Int J Tuberc Lung Dis* 1999;3:847-50.
 83. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. *Am J Respir Crit Care Med* 2003;167:1348-54.
 84. Mitchison DA. Basic mechanisms of chemotherapy. *Chest* 1979;76:771-81.
 85. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. *Clin Chest Med* 1980;1:231-41.
 86. Olsen AW, Brandt L, Agger EM, van Pinxteren LA, Andersen P. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. *Scand J Immunol* 2004;60:273-7.
 87. Cardona PJ, Amati I, Gordillo S, et al. Immunotherapy with fragmented *Mycobacterium tuberculosis* cells increases the effectiveness of chemotherapy against a chronic infection in a murine model of tuberculosis. *Vaccine* 2005;23:1393-8.
 88. Orme IM, Andersen P, Boom WH. T cell response to *Mycobacterium tuberculosis*. *J Infect Dis* 1993;167:1481-97.
 89. Peters AC, Wimpenny JW, Coombs JP. Oxygen profiles in and in the agar beneath colonies of *Bacillus cereus* *Staphylococcus albus* and *Escherichia coli*. *J Gen Microbiol* 1987;133:1257-63.
 90. Robinson TP, Wimpenny JW, Earnshaw RG. pH gradients through colonies of *Bacillus cereus* and the surrounding agar. *J Gen Microbiol* 1991;137:2885-9.
 91. Leserman L. Liposomes as protein carriers in immunology. *J Liposome Res* 2004;14:175-89.
 92. Larson CL, Bell JF, Li RH, Ribi E, Wicht WC. Symposium on relationship of structure of microorganisms to their immunological properties II host-reactive properties of cell walls and protoplasm from mycobacteria. *Bacteriol Rev* 1963;27:341-51.
 93. Dannenberg JR AM. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. *Immunobiology* 1994;191:461-73.
 94. Moreira AL, Shenova L, Aman MH, et al. Mycobacterial antigens exacerbate disease manifestations in *Mycobacterium tuberculosis*-infected mice. *Infect Immun* 2002;70:2100-7.
 95. Taylor JL, Ordway DJ, Trout J, Gonzalez-Juarrero M, Basaraba RJ, Orme IM. Factors associated with severe

- granulomatous pneumonia in *Mycobacterium tuberculosis*-infected mice vaccinated therapeutically with hsp65 DNA. *Infect Immun* 2005;73:5189-93.
96. Brennan PJ. Structure, function, and biogenesis of the cell wall of *Mycobacterium tuberculosis*. *Tuberculosis (Edinburgh)* 2003;83:91-7.
 97. Gil O, Guirado E, Amat I, et al. The control of latent tuberculosis infection after a short-course chemotherapy induced by RUTI is related to the increase of PPD-specific CD8⁺ cells in the lungs and the reduction of pulmonary dissemination through a polyclonal humoral response. New approaches to vaccine development, Berlin, September 2005.
 98. Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. *Infect Immun* 2000;68:1706-9.
 99. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent *Mycobacterium tuberculosis* infection is dependent on CD8 T cells. *Eur J Immunol* 2000;30:3689-98.
 100. Agger EM, Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. *Vaccine* 2002;21:7-14.
 101. Soruri A, Schwyer S, Radzun HJ, Fayyazi A. Mycobacterial antigens induce apoptosis in human purified protein derivative-specific alpha-beta T lymphocytes in a concentration-dependent manner. *Immunology* 2002;105:222-30.
 102. Schaible UE, Winaw F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. *Nat Med* 2003;9:1039-46.
 103. Guirado E, Amat I, Gil O, et al. Passive serum-therapy with polyclonal antibodies against *Mycobacterium tuberculosis* protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. *Microb Infect.* Available online 27 January 2006.
 104. Glatman-Freedman A. Advances in antibody-mediated immunity against *Mycobacterium tuberculosis*: implications for a novel vaccine strategy. *FEMS Immunol Med Microbiol* 2003;39:9-16.
 105. Williams A, Reljie R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. *Immunology* 2004;111:328-33.
 106. Roy E, Stavropoulos E, Brennan J, et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in *Mycobacterium tuberculosis* infection in mice. *Infect Immun* 2005;73:6101-9.
 107. Costello AM, Kumar A, Narayan V, et al. Does antibody to mycobacterial antigens including liparabinomannan limit dissemination in childhood tuberculosis? *Trans R Soc Trop Med Hyg* 1992;86:686-92.
 108. Sanchez-Rodriguez C, Estrada-Chavez C, Garcia-Vigil J, et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2002;6:706-12.
 109. Langermans JA, Andersen P, van Soolingen D, et al. Divergent effect of bacillus Calmette-Guérin BCG vaccination on *Mycobacterium tuberculosis* infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. *Proc Natl Acad Sci USA* 2001;98:11497-502.
 110. Sime PJ, Xing Z, Graham FL, Csaky KG, Gaudie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. *J Clin Invest* 1997;100:768-76.
 111. Demissie A, Abebe M, Aseffa A, et al. Healthy individuals that control a latent infection with *Mycobacterium tuberculosis* express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. *J Immunol* 2004;172:6938-43.
 112. Malhotra I, Mungai P, Wamachi A, et al. Helminth- and *Bacillus Calmette-Guérin*-induced immunity in children sensitized in utero to filariasis and schistosomiasis. *J Immunol* 1999;162:6843-8.
 113. Prescott SL, Macaubas C, Holt BJ, et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. *J Immunol* 1998;160:4730-7.
 114. Gruppo V, Orme IM, editors. Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with *Mycobacterium tuberculosis*. *Tuberculosis (Edinburgh)* 2002;82:267-73.
 115. Jung YJ, LaCourse R, Ryan L, North RJ. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against *Mycobacterium tuberculosis* lung infection in mice. *Infect Immun* 2002;70:6436-43.
 116. Jung YJ, Ryan L, LaCourse R, North RJ. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne *Mycobacterium tuberculosis* infection in mice. *Immunology* 2003;109:295-9.
 117. Turner J, Frank AA, Brooks JV, Gonzalez-Juarrero M, Orme IM. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. *Exp Gerontol* 2001;36:537-45.
 118. Lowrie DB, Tascon RE, Bonato VL, et al. Therapy of tuberculosis in mice by DNA vaccination. *Nature* 1999;400:269-71.
 119. Nuernberger E, Tyagi S, Williams KN, Rosenthal I, Bishal WR, Grosset JH. Rifapentine Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. *Am J Respir Crit Care Med* 2005.
 120. Van Eden W, Van Der Zee R, Van Kooten P, et al. Balancing the immune system: Th1 and Th2. *Ann Rheum Dis* 2002;61(Suppl 2):ii25-8.
 121. Silva CL, Bonato VL, Coelho-Castelo AA, et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. *Gene Ther* 2005;12:281-7.
 122. Rook GA, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting? *Vaccine* 2005;23:2115-20.
 123. Wilkinson K, Kon OM, Newton S, et al. T cell monitoring of treatment for latent tuberculosis infection. In: Sixth international conference on the pathogenesis of mycobacterial infections. Stockholm, Sweden: Salsjöbaden; June 2005.
 124. Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. *Trends Microbiol* 2001;9:115-8.
 125. Lecoq HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. *Am Rev Respir Dis* 1989;140:1189-93.
 126. Cardona PJ, Amat I, Gordillo S, et al. El tratamiento inmunoterápico con RUTI de la infección experimental por *Mycobacterium tuberculosis* también es eficaz en

- huéspedes resistentes a la infección. Abstract XI. Congreso Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Bilbao, Euzkadi, Spain. June 2003.
127. Guirado E, Gil O, Díaz J, et al. Immunotherapy with RUTI is useful in the treatment of latent infection in the experimental model of tuberculosis in guinea pigs. In: Sixth international conference on the pathogenesis of mycobacterial infections. Stockholm, Sweden: Saltsjöbaden; June 2005.
128. Middlebrook G. Immunological aspects of airborne infection: reactions to inhaled antigens. *Bacteriol Rev* 1961;25: 331–46.
129. Perebec SH. Controlled chemoprophylaxis trials in tuberculosis A general review. *Adv Tuberc Res* 1970;17:28–106.

Available online at www.sciencedirect.com



Home

Vaccine Testing

Research Materials

Materials Available

- Cells & Subcellular Fractions
- Native Proteins
- Recombinant Plasmids
- Lipids and Carbohydrates
- Genomic DNA
- Antibodies
- Genomic Arrays
- Transposon Mutants
- Tetramers

**Production Manuals
& SOPs**

Links

Contacts

**Frequently Asked
Questions**

Publications

**BEI Resources
Transition**

Attention

Research materials produced by the TBVTRM Contract are distributed by the Biodefense and Emerging Infections Research Resources Repository (BEI Resources). Please visit [our page](http://www.beiresearch.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx) on the BEI Resources website for complete ordering instructions: <http://www.beiresearch.org/TBVTRMResearchMaterials/tabid/1431/Default.aspx>.

Cell Wall

Reagent:

Cell Wall Fraction, CW

Default Quantity:

1 mg

Production system:

Each strain is grown to late-log phase (day 14) in glycerol-alanine-salts (GAS) medium, washed with PBS pH 7.4 and inactivated by gamma-irradiation. The bacilli are suspended (2 g/ml) in PBS containing 8 mM EDTA, DNase, RNase and a proteinase inhibitor tablet, and broken in a French Press pressure cell at 4°C. Unbroken cells are removed by low speed (3,000 x g) centrifugation. The cell wall is isolated by centrifugation at 27,000 x g for one hour and washed 2 times in PBS. The final cell wall pellet is suspended and dialyzed in 0.01M ammonium bicarbonate, quantified by BCA protein assay for protein content, and stored at -80°C.

Notes:

This preparation contains proteins and non-protein compounds such as mAGP.

References:

[Hirschfield, G.R. et al. J. Bacteriol. 172:1005, 1990.](#)

[Return to Subcellular Fractions](#) | [Return to Materials Available](#)